Protagonist Therapeutics, Inc.
PTGX
Classificação em ações
#2244
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Preço da ação
$138.22
Valor de mercado
$8.94B
Variação (1 dia)
0.16%
Variação (1 ano)
84.29%
País
US
Negociar Protagonist Therapeutics, Inc. (PTGX)
Categoria
Healthcare
Receita da Protagonist Therapeutics, Inc. (PTGX)
Receita em Jun 2026 TTM: $281.99M
De acordo com os últimos relatórios financeiros da Protagonist Therapeutics, Inc., a receita atual da empresa (TTM) é $281.99M. Em 2023, a empresa obteve uma receita de $60.00M um aumento em relação a a receita do ano 2022, que foi de $26.58M. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Protagonist Therapeutics, Inc. de 2014 a 2026
Receita no final de cada ano
| Ano | Receita | Alterar |
|---|---|---|
| 2026 (TTM) | $281.99M | -35.09% |
| 2024 | $434.43M | 624.06% |
| 2023 | $60.00M | 125.73% |
| 2022 | $26.58M | -2.84% |
| 2021 | $27.36M | -4.44% |
| 2020 | $28.63M | 12,293.07% |
| 2019 | $231.00K | -99.25% |
| 2018 | $30.93M | 54.14% |
| 2017 | $20.06M | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
Receita de empresas similares ou concorrentes
| Empresa | Receita | Diferença de Receita | País |
|---|---|---|---|
| $12.62B | 4,376.83% |
US
|
|
| $2.23B | 690.09% |
US
|
|
| $15.74B | 5,483.25% |
AU
|
|
| $6.02B | 2,035.27% |
NL
|
|
| - | - |
CH
|
